Social Links

Follow on Facebook Follow on TwitterFollow EiR on PinterestFollow EiR on Instagram

Xpert Access


Login To Get Involved!

Forgot your username?

Forgot your password?


Join Us At EiR Now!

DNRS Roof Banner


New DNRS 2.0 Available NOW! Improved via Research & Patient Feedback.

Universal AJAX Live Search

Search - Categories
Search - Contacts
Search - Content
Search - Newsfeeds
Search - Weblinks

Double blind, placebo controlled trial of prebiotic, probiotic, and synbiotic supplementation




Am J Clin Nutr. 2009 Sep;90(3):578-86. Epub 2009 Jul 29.


A human, double-blind, placebo-controlled, crossover trial of prebiotic, probiotic, and synbiotic supplementation: effects on luminal, inflammatory, epigenetic, and epithelial biomarkers of colorectal cancer.


Worthley DL, Le Leu RK, Whitehall VL, Conlon M, Christophersen C, Belobrajdic D, Mallitt KA, Hu Y, Irahara N, Ogino S, Leggett BA, Young GP. Royal Brisbane and Women's Hospital Research Foundation, Clinical Research Centre, Brisbane, Australia. This email address is being protected from spambots. You need JavaScript enabled to view it.



BACKGROUND: Diet is an important factor in colorectal carcinogenesis; thus, dietary supplements may have a role in colorectal cancer prevention.


OBJECTIVE: The objective was to establish the relative luminal, epithelial, and epigenetic consequences of prebiotic, probiotic, and synbiotic dietary supplementation in humans.


DESIGN: This was a randomized, double-blind, placebo-controlled, 4-wk crossover trial of resistant starch and Bifidobacterium lactis, either alone or as a combined synbiotic preparation, in 20 human volunteers. Rectal biopsy, feces, and serum samples were collected. The rectal mucosal endpoints were DNA methylation at 16 CpG island loci and LINE-1, epithelial proliferation (Ki67 immunohistochemistry), and crypt cellularity. The fecal endpoints were short-chain fatty acid concentrations, pH, ammonia, and microbiological profiles (by denaturing gradient gel electrophoresis and sequencing). Serum endpoints were a panel of cytokines and high-sensitivity C-reactive protein.


RESULTS: Seventeen subjects completed the entire study. The synbiotic intervention fostered a significantly different fecal stream bacterial community than did either the prebiotic (P = 0.032) or the probiotic (P = 0.001) intervention alone, in part because of a greater proportion of patients harboring fecal Lachnospiraceae spp. These changes developed in the absence of any significant differences in fecal chemistry. There were no differences in epithelial kinetics.


CONCLUSIONS: This synbiotic supplementation with B. lactis and resistant starch, in the doses used, induced unique changes in fecal microflora but did not significantly alter any other fecal, serum, or epithelial variables. This trial was registered in the Australian New Zealand Clinical Trials Registry at as ACTRN012606000115538.


PMID: 19640954 [PubMed - indexed for MEDLINE]



Please Help Support EiR with a Positive Google Review!

Review 'The Environmental Illness Resource' (EiR) on Google


If you like EiR and / or enoyed this content; please help us keep going by leaving a Positive Google Review:
Review EiR on Google NOW!

P.S. This is entirely secure, we collect no data other than what is freely available from Google and you can remain anonymous!


Related Articles:


Mold Testing & Sanitizer:







  • No comments found

Leave your comments

Post comment as a guest

0 Character restriction
Your text should be more than 25 characters
Your comments are subjected to administrator's moderation.
terms and condition.

Adsense Responsive BottomBanner

View the very BEST Environmental Illness Videos!

1. Your Health is Governed by Your Environment | Prof. BM Hegde | TEDx Talk

2. Demystifying Multiple Chemical Sensitivity

3. Social Determinants of Health - An Introduction